APOKYN
AssetAlso called apomorphine hydrochloride injection, Apomorphine, APO, APL-130277
Dopamine receptor agonist that stimulates dopamine receptors to treat motor fluctuations in Parkinson's disease
- Stage
- Approved
- Modality
- Small molecule
- Target
- DRD2
- 6
- Indications
- 25
- Trials
- 1
- Developer
Indications
7No named disease
Approved, open.fda.gov, Apr 20, 2004
Motor symptoms
Phase 3, Completed, NCT01770145, clinicaltrials.gov, Oct 31, 2026
Parkinson's disease
Phase 3, Completed, NCT01770145, clinicaltrials.gov, Oct 31, 2026
4 more
In the full profile
- Target and mechanism4
- Owner and partners1
- Trials25
- Evidence for its targets4
- Competitors12
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.